Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93.37 CHF | +0.81% | +1.14% | +10.02% |
May. 16 | Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 | DP |
May. 16 | Novartis: presents results of tender offer for MorphoSysy | CF |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Sales forecast by analysts have been recently revised upwards.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's enterprise value to sales, at 4.15 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.02% | 210B | B- | ||
+32.09% | 693B | C+ | ||
+29.39% | 584B | B | ||
-1.34% | 372B | C+ | ||
+20.34% | 332B | B- | ||
+7.39% | 294B | C+ | ||
+14.25% | 239B | B+ | ||
-3.03% | 211B | A+ | ||
+8.49% | 168B | C+ | ||
-0.52% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- Ratings Novartis AG